Shares of DIAGENS-B (02526) climbed more than 23% intraday before paring gains to trade 21.27% higher at HK$402.60, with turnover reaching HK$19.496 million. The rally follows Monday's announcement by Moderna and Merck, who revealed preliminary positive results from the first Phase III trial of their jointly developed mRNA personalized cancer vaccine—marking the world's first mRNA cancer therapy to demonstrate efficacy in a Phase III study. Moderna's US shares skyrocketed 176.97% overnight, while the Nasdaq Biotechnology Index surged 6.4%, its biggest single-day gain in six years.

This news directly ignited sentiment across Hong Kong's biotech sector, with innovative drug and vaccine names trading broadly higher. Meanwhile, the ongoing AI4S theme continues to gain traction, boosting market interest in AI-powered drug discovery, and driving strength in pharmaceutical AI and large-model stocks. DIAGENS-B recently published its interim results for fiscal 2026, showing total operating revenue of RMB 108.7 million, up 21.0% year-over-year. Gross profit reached RMB 80.504 million, up 14.0%, while the comprehensive gross margin held steady at a robust 74.1%.

Notably, model service revenue for the period hit RMB 94.541 million, a dramatic 101.1% increase from the prior year. This segment now accounts for 87% of total revenue, up from 52% in the same period last year, positioning it as the core growth engine driving the company's top-line expansion.